Results 91 - 100 of 122
Researchers
| Name | Track | Location | View profile |
|---|---|---|---|
| Regenerative Science, Virology and Gene Therapy | Minnesota | ||
IntroductionDr. Patricia Devaux is a Senior Associate Consultant II and Assistant Professor in Molecular Medicine, with appointments in the VGT and REGS programs. A trained virologist, she studies measles virus and its use in therapeutic applications. An award-winning educator (VGT Teacher of the Year, 2021), she is dedicated to mentoring trainees at all levels. Her interdisciplinary research develops measles-based tools for gene delivery, stem cell generation, and genome editing, with the goal of creating new treatments for diseases such as sickle cell disease, β-thalassemia, and Parkinson’s disease. She fosters a supportive, collaborative lab environment where trainees gain hands-on experience and prepare for careers in biomedical research. |
|||
| Molecular Pharmacology and Experimental Therapeutics | Arizona | ||
IntroductionTrainees in the Urrutia Lab learn to think across scales — from single DNA variants and protein domains to chromatin complexes, regulatory networks, and disease phenotypes. Projects often begin with genomic or structural data and ask how molecular changes alter function, reshape cellular programs, and create opportunities for diagnosis or therapy. The training environment reflects a long-standing commitment to mentorship and team science, including guiding more than 50 scientists and building multidisciplinary collaborations. Trainees are encouraged to develop as independent scientists who can move comfortably between data, mechanism, and clinical relevance while contributing to precision medicine for cancer and rare diseases. |
|||
| Immunology | Minnesota | ||
IntroductionThe goal of my research is to better understand how immune responses develop after vaccination. This knowledge can be applied toward improving current vaccines, understanding the causes of and thereby avoiding vaccine adverse events, and informing the development of novel vaccines that protect against existing and newly emerging pathogens. Basically, getting the right person the right vaccine at the right time. My lab focuses primarily on vaccines against viral pathogens, such as influenza, measles, mumps, rubella, RSV, smallpox, mpox, SARS-CoV-2, and zoster. |
|||
| Clinical and Translational Science | Minnesota | ||
IntroductionDr. Sharp's current research examines how patients and healthcare providers view new forms of personalized medicine and clinical interventions enabled by molecular diagnostics and digital health technologies. |
|||
| Molecular Pharmacology and Experimental Therapeutics | Minnesota | ||
IntroductionThis research program has, over the years, sequentially incorporated advances in analytical techniques to identify and study individual variation in the pharmacologic therapy of disease, with special emphasis on neuropsychiatric disorders such as Major Depressive Disorder (MDD) or Alcohol Use Disorder (AUD). These studies have resulted in the identification of novel genes responsible for variation in disease pathophysiology as well as novel pathways for drug response and new drug development. |
|||
| Biochemistry and Molecular Biology, Clinical and Translational Science, Immunology, Molecular Pharmacology and Experimental Therapeutics, Virology and Gene Therapy | Minnesota | ||
Introduction
Dr. Patel's research focuses on microbial biofilms and antibacterial resistance. Her lab focuses on new diagnostics and therapeutics for biofilm-associated infections, including periprosthetic joint infections, endocarditis, catheter-associated infections and wound infections. She also focuses on evaluation of new antibacterial therapies in vitro and in vivo, emerging pathogens and their pathogenesis, and diagnostic approaches that address antibacterial resistance.
|
|||
| Biochemistry and Molecular Biology, Immunology, Neuroscience, Regenerative Science | Florida | ||
IntroductionThe diverse team of researchers led by Dr. Da Mesquita is focused on determining and testing the factors that increase the risk for neurological diseases by mediating long-lasting changes in the meningeal lymphatic vasculature and in central nervous system immunity. Employing complementary approaches including genetically modified mice, human tissue and fluid samples, and state-of-the-art techniques, like in vivo fluorescence microscopy, flow cytometry, and single-cell RNA sequencing, Dr. Da Mesquita and his team aim at understanding how the meningeal lymphatic vasculature modulates brain function along the mammalian lifespan, and is able to affect the progression and outcome of neurodegenerative diseases like Alzheimer’s and Parkinson's. |
|||
| Molecular Pharmacology and Experimental Therapeutics | Minnesota | ||
IntroductionMy goal is to improve the therapy of neoplastic diseases, focusing on acute leukemias and ovarian cancers. As a mentor, I strive to see that my trainees learn to recognize and address impactful problems, conduct rigorous and insightful experiments, and pursue answers to their questions wherever the science leads. Previous postdoctoral fellows from the laboratory are serving as cancer center directors (two) or leading research activities in academia or biotech. Previous Ph.D. students from the laboratory are leading major efforts in biotech or running their own independent laboratories in academia. |
|||
| Clinical and Translational Science | Arizona | ||
IntroductionDr. Shannon Fortin Ensign is a Neuro-Oncologist and Physician-Scientist at Mayo Clinic whose translational research focuses on the molecular mechanisms driving glioma progression and therapeutic resistance, particularly in IDH-mutant astrocytoma. Her lab integrates functional genomics, cell signaling, spatial and single-cell transcriptomics, and patient-derived datasets to define tumor–microenvironment interactions that promote disease progression, with the goal to uncover therapeutic vulnerabilities. Her group seeks to identify biologically informed therapeutic targets and biomarkers to inform future treatment strategies and clinical trial development. She is committed to mentoring the next generation of scientists. |
|||
| Biomedical Engineering and Physiology | Minnesota | ||
IntroductionDr. Shigao Chen’s research focuses on developing innovative ultrasound technologies to address critical clinical needs. His work centers on next-generation quantitative ultrasound imaging methods for accurate disease assessment, with a strong emphasis on translating innovations from bench to bedside to improve patient care. Technologies he helped develop—including Comb-push Ultrasound Shear Elastography, liver steatosis quantification, and super-resolution ultrasound imaging—have been licensed by GE, Samsung, and other leading ultrasound companies, implemented on clinical scanners, and adopted worldwide. He also collaborates with clinicians to explore emerging therapeutic applications of ultrasound. |
|||